Vaccinex, Inc. (VCNX) Stock Price & Analysis
Vaccinex, Inc. (VCNX) rose 54.05% to USD 1.19 as of June 10, 2026 at 10:13 UTC, according to Nexqual real-time market data.
VCNX last closed at USD 0.77; the session ranged USD 0.77–1.19 on volume of 4,408 shares. Market capitalization is $3.19M, with a 52-week range of USD 0.31–1.5 (PNK). Source: Nexqual, June 10, 2026 at 10:13 UTC.
Key Statistics (as of June 10, 2026 at 10:13 UTC)
| Price | USD 1.19 |
|---|---|
| Change | ▲ 54.05% (up) |
| Previous Close | USD 0.77 |
| Open | USD 0.78 |
| Day Range | USD 0.77 – 1.19 |
| 52-Week Range | USD 0.31 – 1.5 |
| Volume | 4,408 shares |
| Market Cap | $3.19M |
| Exchange | PNK |
Technical Analysis (VCNX)
Nexqual's technical model rates VCNX "SELL" based on 1 bullish and 4 bearish signals across 123 daily candles, as of June 10, 2026 at 10:13 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 49.34 (neutral) |
| vs SMA50 | Above (USD 1.02) |
| MACD | -0.02 (negative) |
Analyst Ratings (VCNX)
Wall Street analysts rate VCNX "None", per Nexqual as of June 10, 2026 at 10:13 UTC.
| Consensus Rating | None |
|---|
Earnings (VCNX)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2021-06-30 | USD -44.1 vs est -60.9 ▲ beat |
| 2021-03-31 | USD -54.6 vs est -81.9 ▲ beat |
| 2020-12-31 | USD -54.6 vs est -78.75 ▲ beat |
| 2020-09-30 | USD -92.4 vs est -91.35 ▼ miss |
Source: Nexqual, June 10, 2026 at 10:13 UTC.
Financials & Fundamentals (VCNX)
| Total Revenue | $601,000 |
|---|---|
| Gross Margin | +0.00% |
| Operating Margin | -1590.14% |
| Profit Margin | +0.00% |
| Current Ratio | 0.5 |
| Total Cash | $1.11M |
| Total Debt | $25,000 |
| Free Cash Flow | $-11.54M |
Source: Nexqual, June 10, 2026 at 10:13 UTC.
Financial Health Score (VCNX)
Nexqual rates Vaccinex, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 10:13 UTC.
| Growth | Strong — Revenue +20% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $1M cash, no debt |
| Cash Flow | Weak — FCF negative: -$12M, burning cash |
| Efficiency | Mixed — No data |
Ownership (VCNX)
| Insider Ownership | +11.48% |
|---|---|
| Institutional Ownership | +45.01% |
| Shares Outstanding | 2.68M |
| Float | 1.18M |
| Short % of Float | +3.23% |
Source: Nexqual, June 10, 2026 at 10:13 UTC.
Leadership (VCNX)
Vaccinex, Inc. is led by Maurice Zauderer (age 79), Co-Founder, CEO, President & Director, per Nexqual as of June 10, 2026 at 10:13 UTC.
| Co-Founder, CEO, President & Director | Maurice Zauderer (age 79) |
|---|---|
| COO and Senior VP of Discovery & Translational Medicine | Elizabeth E. Evans (age 53) |
| Senior VP of Research & Chief Scientific Officer | Ernest S. Smith (age 53) |
| Chief Financial Officer | Jill Sanchez (age 53) |
From Vaccinex, Inc.'s Latest SEC 10-K Filing (filed 2025-04-15)
Key Strengths & Strategy (as disclosed to the SEC)
- Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders.
- The company's lead drug candidate is pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D.
- The company has also developed ActivMAb, a human antibody discovery platform based on a novel method for expressing and presenting complex multipass membrane proteins, as well as full-length human monoclonal antibodies on the surface of mammalian pox viruses.
- In addition, it develops CHS-114 and anti-CCR8 antibody; and VX5, which is in preclinical development to treat related to autoimmune disorders.It has collaborations with Merck Sharp & Dohme; Ares Trading S.A.; Emory University; Huntington Study Group; Catalent Pharma Solutions, LLC; and Surface Oncology, Inc.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ENTX | Entera Bio Ltd. | USD 1.22 | ▲ 3.39% |
| ATHE | Alterity Therapeutics Limited | USD 4.29 | ▲ 10% |
| ATXI | Avenue Therapeutics, Inc. | USD 0.36 | ▲ 2.27% |
| LIXT | Lixte Biotechnology Holdings, I | USD 6.87 | ▼ 1.86% |
| ADIL | Adial Pharmaceuticals, Inc | USD 2.13 | ▼ 3.62% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 10:13 UTC. This page is informational and not investment advice.